PDL BioPharma (PDLI) Posts Q1 EPS of $0.04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
PDL BioPharma Announces First Quarter 2017 Financial Results
May 3, 2017 4:02 PM EDTINCLINE VILLAGE, Nev., May 3, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2017 including:
Total revenues of $45.4 million for the three months ended March 31, 2017. GAAP diluted EPS of $0.04 for the three months ended March 31, 2017. GAAP net income attributable to PDL's shareholders of $7.2 million for the three months ended March 31, 2017. Non-GAAP net income attributable to PDL's shareholders of $13.2 million for the three months ended March 31, 2017. A full... More